Drug intelligence / Profile preview

Zhengyuan Capsule

Development stage: Phase 4
Lead developer: Qiang Fu
Modality: Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
Administration: Oral

Overview

Zhengyuan Capsule is a Traditional Chinese Medicine (TCM) formulation developed by Qiangfu Biotech for the treatment of cancer-related fatigue (CRF). It is specifically being evaluated in patients with breast cancer who have completed primary anti-tumor therapies such as surgery, chemotherapy, or radiotherapy. The capsule is designed to alleviate symptoms of fatigue and improve the overall quality of life by tonifying qi, a central concept in TCM for restoring energy and vitality. A Phase 4 clinical trial (NCT05483400) is currently investigating its effectiveness and safety in this patient population.

Brand names: Zhengyuan Capsule
Other names: Zhengyuan Jiaonang

Beyond the preview

Go deeper on Zhengyuan Capsule.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Zhengyuan Capsule.

Explore the full profile